ReNeuron Group Plc (LON:RENE) has been awarded a further grant by the Welsh Government to advance its emerging exosome therapy platform.
The grant, awarded under the SMARTExpertise scheme, will help fund a £1.2m collaborative programme of work to be undertaken by ReNeuron, Ig Innovations and Swansea University Medical School.
READ: ReNeuron presents more data on potential for its Exosome therapy as cancer treatment
Exosomes are nano-sized particles in the bloodstream and other body fluids that can be absorbed by other cells.
New research, including by ReNeuron, points to them having a major impact on the way cells behave with a number of advantages in therapeutic treatments, especially in the way they can be engineered to be strong and precise delivery mechanisms.
ReNeuron will use the new grant to optimise the manufacture of CTX cell-derived exosomes, enhance them against solid tumours to identify new cancer targets and methods to characterise exosomes with potential therapeutic benefit.
WATCH: It's 'all systems go' as ReNeuron gears up for Phase III stroke disability study
The exosome therapy platform is being developed as a potential new nano-medicine targeting cancer and as a potential delivery system for drugs that would otherwise be unable to reach their site of action.
Dr Randolph Corteling, Reneuron’s head of research, said: “As a Wales-based business, we are very pleased to be able to work with leading Welsh academic and industry collaborators."